Izotropic Provides Marketing Update

Rhea-AI Summary

Izotropic Corporation, a medical device company focused on breast cancer imaging technology, has engaged Evolux Capital for marketing services. The six-month contract, ending December 11, 2025, includes social media advertising, communications strategy, and brand development. As compensation, Evolux will receive 200,000 Restricted Share Units (RSUs) before service commencement. Additionally, the company issued 60,000 RSUs to consultants, bringing the total RSU issuance to 260,000 units under their Long Term Incentive Plan, all vesting immediately.

Positive

• Company is investing in marketing and brand development to increase market presence
• Strategic engagement of marketing services without cash expenditure through RSU compensation

Negative

• Issuance of 260,000 RSUs may lead to potential shareholder dilution

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 13, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into an agreement with 1822053 Alberta Ltd. (d/b/a Evolux Capital) ("Evolux") to provide marketing services to the Company. The services are expected to include the creation and distribution of social media advertising, development and implementation of communications strategies, assisting with brand development, and coordinating with social media and advertising partners.

Evolux is an arm's-length marketing firm and has been engaged for an initial six-month term, ending December 11, 2025, for a total consideration of 200,000 Restricted Share Units ("RSUs"), to be paid in full prior to the commencement of services. The RSUs shall be granted in accordance with the issuer's equity incentive plan and applicable regulatory approvals. Evolux can be contacted at evoluxcapital@gmail.com or 126 Mitchell Crescent, Blackfalds, Alberta, T4M 0H6.

The Company has also issued 60,000 RSUs to certain Consultants.

Pursuant to the Company's Long Term Incentive Plan, 260,000 RSUs have been issued and vest immediately.

About Izotropic:
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR+ at sedarplus.ca.

Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.

Contacts:

Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com

James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2

General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255456

FAQ

What marketing services will Evolux provide to Izotropic Corporation (IZOZF)?

Evolux will provide social media advertising, communications strategy development, brand development, and coordination with social media and advertising partners for a six-month term ending December 11, 2025.

How much compensation will Evolux receive for their marketing services to IZOZF?

Evolux will receive 200,000 Restricted Share Units (RSUs) as compensation, to be paid in full before services begin.

How many total RSUs did Izotropic Corporation (IZOZF) issue in this announcement?

Izotropic issued a total of 260,000 RSUs - 200,000 to Evolux Capital and 60,000 to certain consultants.

When will the RSUs issued by IZOZF vest?

All 260,000 RSUs vest immediately according to the Company's Long Term Incentive Plan.